Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan plus osimertinib vs osimertinib in first-line EGFR-mutant non-squamous NSCLC (China)
CTR20254635Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telisotuzumab adizutecan, osimertinib in Non-small cell lung cancer (NS-NSCLC), sponsored by AbbVie Inc.. Started Jul 2026; status: active.
02
Drugs
telisotuzumab adizutecanosimertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20254635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254635.